Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | VNN1 | O95497 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155314 | 0.90 | VNN1 (0.55) | MAP4K4SCN2ASCN10ACLK1FYN | |
| SCHEMBL4155055 | 0.90 | FYN (0.53) | CLK1FYNCNR1VNN1HDAC1 | |
| SCHEMBL4155753 | 0.89 | S1PR1 (0.46) | CLK1FYNVNN1HDAC1HDAC8 | |
| SCHEMBL4156327 | 0.87 | CLK1 (0.50) | CLK1FYNVNN1HDAC1HDAC8 | |
| SCHEMBL4140370 | 0.86 | CLK1 (0.48) | CLK1FYNVNN1HDAC1HDAC8 | |
| SCHEMBL4148171 | 0.86 | MAP4K4 (0.52) | MAP4K4CLK1FYNVNN1HDAC1 | |
| SCHEMBL4140030 | 0.85 | FYN (0.53) | CLK1FYNVNN1HDAC1HDAC8 | |
| SCHEMBL4143243 | 0.84 | FYN (0.57) | CLK1FYNVNN1RETCYP11B2 | |
| SCHEMBL4143026 | 0.84 | MKNK1 (0.50) | CLK1FYNVNN1HDAC1MKNK1 | |
| SCHEMBL4199231 | 0.83 | XDH (0.57) | MAP4K4FYNCNR1NR4A2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | MAP4K4 75/4885SCN2A 4701/4885SCN10A 3907/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | MAP4K4 546/4885SCN2A 3155/4885SCN10A 1389/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | MAP4K4 546/4885SCN2A 3155/4885SCN10A 1389/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | MAP4K4 546/4885SCN2A 3155/4885SCN10A 1389/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | MAP4K4 600/4885SCN2A 1548/4885SCN10A 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.